Herpes Virus Therapy of Prostate Cancer
Abstract
Conditionally replicating herpes vectors offer unique advantages for cancer therapy. We have studied vector constructs with increased anti-tumor efficacy and demonstrated that the NV-series of vectors are more efficacious in the mouse prostate cancer models than the G-series of vectors. Moreover, in a bilateral tumor model, the lL-12 containing vector, NV1042, causes a markedly significant tumor growth inhibition of the treated tumor and lesser but significant inhibition of the untreated tumor as well. Further, in studies of systemic administration, we found that NV 1023 and NV1O42 can be administered safely intravenously in mice and that G207, NV1023, and NV1O42 show efficacy after intravenous administration in a mouse Tramp model system. This work for the first time demonstrates that two different transgenic systems can be used to study efficacy of herpes oncolytic vectors. This will allow us to then study these vectors in the tumors occurring in situ in these transgenic animals and also will allow us to study improvements in these vector systems which we expect to ultimately translate into clinical trials.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2002
- Accession Number
- ADA410713
Entities
People
- Robert L. Martuza
Organizations
- Massachusetts General Hospital